Product Data - D12079B

Description
RD Western Diet

Used in Research
Obesity
Diabetes
Osteoporosis
Hypertension
Atherosclerosis
Metabolic Syndrome

Packaging
Product is packed in 12.5 kg box.
Each box is identified with theproduct name, description, lot
number and expiration date.

Lead Time
5-7 business days.

Gamma-Irradiation
Yes. Add 10 days to delivery time.

Form
Pellet, Powder, Liquid

Shelf Life
Most diets require storage in a cooldry environment. Stored correctly
they should last 6 months.

Control Diets
Custom diets available on request.

ReportRepeatReviseFormula
Product # D12079BProtein
Carbohydrate
FatTotal
kcal/gm

gm%kcal%2050
21174341100

4.7

Ingredient

gm

kcal

Casein, 80 MeshDL-Methionine

1953780
12Corn StarchMaltodextrin 10Sucrose

50
100341200
4001364Cellulose

500Milk Fat, Anhydrous*Corn Oil

200
10180090

Mineral Mix S10001
Calcium Carbonate

35400Vitamin Mix V10001
Choline Bitartrate

10240Cholesterol, USP*
Ethoxyquin

1.50.04

001001.54

4686

Total

0*Anhydrous milk fat typically contains approximately 0.3% cholesterol.
On this basis, D12079B contains approximately 0.21% cholesterol.
Formulated by E. A. Ulman, Ph.D., Research Diets, Inc., October 12, 1995.
Diet formulated to match Teklad Western Diet #TD88137, except that 1%Corn Oil replaces 1% Butter Fat.

Where NutriPhenomics Begins

Research Diets, Inc.
20 Jules Lane
New Brunswick, NJ 08901 USA
Tel: 732.247.2390
Fax: 732.247.2340
info@researchdiets.com© 2006 Research Diets, Inc. All rights reserved. D12079B--6-12

References - D12079B

ReportRepeatRevise1. Beigneux, A.P., et al. ATP-Citrate lyase deficiency in the mouse. Journal of Biological Chemistry. 279:9557-9564, 2004.
2. Bhat, B.G. et al. Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.
Journal of Lipid Research. 44:1614-1621, 2003.
3. Collins, A.R. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein
receptor-deficient mice. Arterioscler Thromb. Vasc. Biol. 21:365-371, 2001.
4. Davis, H.R., et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibit the development of atherosclerosis in ApoE
knockout mice. Arterioscler Thromb. Vasc. Biol. 21:2032-2038, 2001.
5. Lemaître, V., et al. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient intissue inhibitor of metalloproteinases-1. Circulation. 107:333-338, 2003.
6. Lemaître, V. et al. ApoE knockout mice expressing human matrix metalloproteinase-1 macrophages have less advanced atherosclerosis.
Journal of Clinical Investigation. 107:1227-1234, 2001.
7. Ogus, S. et al. Hyperleptinemia precipitates diet-induced obesity in transgenic mice overexpressing leptin.
Endocrinology. 144:2865-2869, 2003.
8. Park, Tae-Sik, et al. Inhibition of sphingomyelin synthesis reduces atherogeneesis in apolipoprotein E-knockout mice.
Circulation. 110:3465-3471, 2004.
9. Seli, E., et al. Estradiol suppresses vascular monocyte chemotactic protein-1 expression during early atherogenesis.
Am. J. Obstet. Gynecol. 187:1544-1549, 2002.

Where NutriPhenomics Begins

Research Diets, Inc.
20 Jules Lane
New Brunswick, NJ 08901 USA
Tel: 732.247.2390
Fax: 732.247.2340
info@researchdiets.com© 2006 Research Diets, Inc. All rights reserved. D12079B--6-12